Author | Axel Grothey, MD | OncLive

Author | Axel Grothey, MD


Dr. Grothey on FDA Approval of Pembrolizumab in MSI-High CRC

May 24, 2017


Axel Grothey, MD, medical oncologist at Mayo Clinic, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with microsatellite instability-high colorectal cancer (CRC).

Dr. Grothey on Treatment Landscape of mCRC

February 28, 2017


Axel Grothey, MD, medical oncologist, Mayo Clinic, discusses some of the therapeutic approaches in the field of metastatic colorectal cancer (CRC).

Dr. Axel Grothey on Differences Between CORRECT and CONCUR Studies in mCRC

July 16, 2015


Axel Grothey, MD, department of Oncology, Mayo Clinic, Rochester, MN, discusses the differences between the CORRECT and CONCUR trials, which both looked at regorafenib for previously treated metastatic colorectal cancer (mCRC).

Dr. Grothey on Bevacizumab Beyond Progression in mCRC

February 22, 2013


Axel Grothey, MD, from the Mayo Clinic in Rochester, Minnesota, discusses the effectiveness of bevacizumab beyond disease progression in metastatic colorectal cancer.